'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed...
'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed...
默沙東與伊克力西斯合作,在腎癌中測試Zanzalintinib與Welireg聯用,保持激酶抑制劑期權開放;合作引發關於默沙東正在進行的與樂普瑞、Litespark-011試驗完成日期延遲的疑問...